ObjectiveTo evaluate the safety and efficacy of 2 doses of dexamethasone intravitreal implant (DEX implant) for treatment of noninfectious intermediate or posterior uveitis.MethodsIn this 26-week trial, eyes with noninfectious intermediate or posterior uveitis were randomized to a single treatment with a 0.7-mg DEX implant (n = 77), 0.35-mg DEX implant (n = 76), or sham procedure (n = 76).Main Outcome MeasureThe main outcome measure was the proportion of eyes with a vitreous haze score of 0 at week 8.ResultsThe proportion of eyes with a vitreous haze score of 0 at week 8 was 47% with the 0.7-mg DEX implant, 36% with the 0.35-mg DEX implant, and 12% with the sham (P < .001); this benefit persisted through week 26. A gain of 15 or more letters from baseline best-corrected visual acuity was seen in significantly more eyes in the DEX implant groups than the sham group at all study visits. The percentage of eyes with intraocular pressure of 25 mm Hg or more peaked at 7.1% for the 0.7-mg DEX implant, 8.7% for the 0.35-mg DEX implant, and 4.2% for the sham (P > .05 at any visit). The incidence of cataract reported in the phakic eyes was 9 of 62 (15%) with the 0.7-mg DEX implant, 6 of 51 (12%) with the 0.35-mg DEX implant, and 4 of 55 (7%) with the sham (P > .05).ConclusionsIn patients with noninfectious intermediate or posterior uveitis, a single DEX implant significantly improved intraocular inflammation and visual acuity persisting for 6 months.Application to Clinical PracticeDexamethasone intravitreal implant may be used safely and effectively for treatment of intermediate and posterior uveitis.Trial Registrationclinicaltrials.gov Identifier: NCT00333814
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Dexamethasone intravitreal implant. A, Placement of the dexamethasone intravitreal implant in the vitreous. B, Degradation of the implant over time: at administration (left) and after 3 weeks (right).
Flowchart of patient disposition. DEX implant indicates dexamethasone intravitreal implant.
Eyes with a vitreous haze score of 0. A, All eyes. B, Eyes with a baseline vitreous haze score of +1.5 or +2. C, Eyes with a baseline vitreous haze score of +3 or +4. When significant, P values are shown for the 0.7-mg dexamethasone intravitreal implant (DEX implant) vs sham. *One patient in the 0.7-mg DEX implant group with a baseline vitreous haze score of +1 was excluded from the analysis.
Eyes with at least 2 units of improvement in vitreous haze score. When significant, P values are shown for the 0.7-mg dexamethasone intravitreal implant (DEX implant) vs sham. The differences between the 0.35-mg DEX implant group and the sham group were statistically significant at week 3 (P = .034) and weeks 6 to 26 (P ≤ .003).
Best-corrected visual acuity (BCVA). A, Eyes achieving a 15-letter or more improvement from baseline BCVA. B, Change from baseline BCVA. P > .05 for the 0.7-mg vs 0.35-mg dexamethasone intravitreal implant (DEX implant). P values are in comparison with the sham procedure.
Cumulative percentage of eyes requiring rescue medication in the study eye at each visit. P values are for the 0.7-mg dexamethasone intravitreal implant (DEX implant) vs the sham procedure.
Percentage of eyes with notable changes in intraocular pressure (IOP). A, Percentage of eyes with IOP of at least 35 mm Hg. B, Percentage of eyes with IOP of at least 25 mm Hg. DEX implant indicates dexamethasone intravitreal implant.
Intraocular pressure (IOP)–lowering medication use in the 0.7-mg dexamethasone intravitreal implant (DEX implant) group only.
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Thank you for submitting a comment on this article. It will be reviewed by JAMA Ophthalmology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 20
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature Table 9.2-3 Refuted Evidence From Observational Studiesa
All results at JAMAevidence.com >
and access these and other features:
Register Now
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Need assistance?
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.